CRA interviews are brutally specific. Interviewers at CROs like ICON, IQVIA, Syneos, and PPD don't ask hypotheticals — they ask how you handled an actual protocol deviation, what you did when a site was out of compliance, and whether you can quote ICH E6(R2) from memory. If you can't answer those, you're out. Here's how to prepare.
What CRA Interviews Actually Test
Whether you're applying as an entry-level CRA at a CRO or a senior CRA at a sponsor company, the core interview format is the same:
- GCP and regulatory knowledge — ICH E6(R2), FDA 21 CFR Parts 11/50/54/56, and EU Clinical Trials Regulation
- Monitoring visit competency — SQVs, SIVs, routine monitoring visits (RMVs), close-out visits (COVs)
- Site management judgment — handling non-compliance, protocol deviations, data discrepancies
- Tools and systems — CTMS, EDC systems, and eTMF familiarity
- Behavioral scenarios — how you handle difficult investigators, sponsor pressure, and competing priorities
Entry-Level CRA vs. Senior CRA: What Changes
Entry-level CRA interviews focus on foundational GCP knowledge, your internship or CRC experience, and your ability to learn SOPs quickly. They'll probe whether you understand the difference between a protocol deviation and a protocol violation, and whether you've ever participated in a monitoring visit in any capacity.
Senior CRA interviews go deeper. Expect questions about escalation judgment (when do you escalate to management vs. handle it yourself?), site risk scoring, managing underperforming sites, and experience with regulatory inspections. You may also be asked about therapeutic area expertise — oncology CRAs face different site challenges than CNS or cardiology.
10 Real CRA Interview Questions and How to Answer Them
1. "Walk me through the difference between a protocol deviation and a protocol violation."
A deviation is an unintentional, non-recurring departure from the protocol — a patient took a dose 2 days late. A violation is a more serious departure that may affect subject safety or data integrity, such as enrolling a patient who didn't meet inclusion criteria. Violations typically require immediate escalation to the sponsor and may need regulatory reporting. Always mention that all deviations must be documented and assessed for their impact on subject safety and data validity under ICH E6(R2) Section 4.5.
2. "How do you prepare for a site initiation visit (SIV)?"
Walk through your actual checklist: confirming IRB/IEC approval is current, verifying the investigational product (IP) has arrived and is stored correctly, reviewing staff delegation logs, confirming the site has a working EDC account and training is complete, and checking that the informed consent form (ICF) has been approved in the current version. Mention that you review the protocol one more time before the visit and prepare a site-specific agenda.
3. "You arrive at a site and discover the IP is being stored at the wrong temperature. What do you do?"
This is a GCP compliance scenario. The right answer: immediately quarantine the affected IP, document the finding in your monitoring visit report, notify the sponsor's medical monitor and the site pharmacist or PI. Determine whether any subjects received potentially compromised product. If so, the PI may need to notify the IRB and subjects. The IP temperature log must be retained in the TMF. Don't say you'd "talk to the site coordinator" — escalation here is non-negotiable.
4. "Describe your experience with source data verification (SDV) and source data review (SDR)."
SDV = comparing data entered in the EDC against original source documents line by line. SDR = a risk-based review that looks at critical data points and trends without 100% SDV. Know that ICH E6(R2) encourages risk-based monitoring, so many sponsors have moved to SDR-first approaches. If you've used Medidata Rave or Veeva Vault for EDC, name them. Mention any experience with centralized statistical monitoring (CSM) if relevant.
5. "A site coordinator tells you the PI signed the consent forms on behalf of patients because the PI was in a rush. How do you handle this?"
This is an informed consent violation — a serious GCP issue. The investigator cannot sign on behalf of subjects. Patients have the right to review, ask questions, and sign for themselves. You document it as a protocol deviation (potentially a violation depending on severity), notify the sponsor's medical monitor, and work with the PI to implement corrective and preventive action (CAPA). Depending on the number of affected subjects, the IRB may need to be notified.
6. "How do you handle a site that consistently submits late or incomplete case report forms (CRFs)?"
Show a structured approach: first, understand the root cause — is it a staffing issue, training gap, or EDC access problem? Then work with the site coordinator on a remediation plan with specific deadlines. Document all communications in the site visit report and CTMS. Escalate to the sponsor and consider a for-cause visit if the pattern persists after two monitoring cycles. Name-drop your CTMS experience (Medidata Rave, Oracle Clinical, Veeva Vault) if you have it.
7. "What's the process for submitting a serious adverse event (SAE) report?"
Sites are required to report SAEs to the sponsor within 24 hours of awareness (or within the timeline defined in the protocol, often 24-72 hours). The sponsor then has regulatory timelines: expedited reporting to the FDA for unexpected SUSARs (Suspected Unexpected Serious Adverse Reactions) within 7 days for fatal/life-threatening events, 15 days for others. Know ICH E2A and that you always verify the site has completed MedWatch Form 3500A (US) or CIOMS Form (international). As the CRA, your role is to confirm the SAE was reported, documented, and followed up.
8. "What EDC and CTMS platforms have you worked with? What are the limitations of each?"
Medidata Rave is the most common EDC — mention its query management and audit trail features. Veeva Vault eTMF is widely used for document management. Oracle InForm is common in older studies. On CTMS, mention Oracle CTMS, Veeva CTMS, or Medidata CTMS. Interviewers aren't looking for perfection — they want to see you can speak intelligently about the tools, understand what they track, and adapt to new systems.
9. "You're monitoring a Phase III oncology trial and you discover the site has been enrolling patients outside the protocol's age range. How do you proceed?"
This is a major protocol deviation potentially affecting subject safety. Document immediately in your monitoring visit report. Issue a protocol deviation notice. The PI must notify the IRB within the required timeframe (usually 5-10 business days). Determine whether the deviation affects any efficacy or safety endpoints. Work with the sponsor's medical monitor on a CAPA plan. If the pattern is systemic, a for-cause visit may be warranted and regulatory authorities may need to be notified depending on the country.
10. "What does risk-based monitoring (RBM) mean to you in practice?"
RBM is the ICH E6(R2)-endorsed approach of focusing monitoring resources on the highest-risk data, sites, and processes. In practice, it means: using centralized monitoring dashboards to flag statistical outliers in enrollment, protocol deviations, and lab values; applying site risk scores to determine visit frequency; and shifting some SDV effort to SDR. The goal is to maintain subject safety and data integrity without requiring 100% on-site SDV. Interviewers want to see you can articulate this — it signals maturity beyond checkbox monitoring.
GCP Concepts You Must Know Cold
- ICH E6(R2) — the foundation of GCP; know sections on sponsor responsibilities, investigator responsibilities, monitoring, and essential documents
- 21 CFR Part 11 — electronic records and signatures (US)
- 21 CFR Part 50 — informed consent (US)
- 21 CFR Part 56 — IRB requirements (US)
- EU Clinical Trials Regulation (CTR) No 536/2014 — for EU-based or multinational studies
- TMF Reference Model — know what belongs in the Trial Master File and the difference between sponsor TMF and investigator site file (ISF)
Tools to Know Before Your Interview
- EDC: Medidata Rave, Veeva Vault EDC, Oracle InForm, REDCap (academic)
- eTMF: Veeva Vault TMF, Trial Interactive, Arisglobal
- CTMS: Veeva CTMS, Medidata CTMS, Oracle CTMS
- Safety reporting: Argus Safety, Oracle Safety (ARISg)
Preparing for the Behavioral Round
CRA behavioral questions use STAR (Situation, Task, Action, Result). Prepare stories for:
- A time you identified a GCP non-compliance issue and how you handled it
- A conflict with a site coordinator or PI and how you resolved it
- A time you managed competing monitoring visit deadlines
- A situation where you had to deliver bad news to a sponsor or site
Practice your answers out loud. CRA interviewers are experienced monitors — vague answers won't fly.
The Week Before Your Interview
- Review the job description for specific therapeutic areas or phases — if they mention oncology Phase II/III, refresh your SAE reporting timelines and protocol deviation workflows for those contexts
- Look up the company's pipeline (ClinicalTrials.gov) to understand what they actually run
- Prepare 3-5 specific examples from your monitoring experience, with numbers where possible ("I managed 8 sites across 3 states, monitored quarterly")
CRA interviews reward preparation depth, not breadth. Know GCP cold, have real examples ready, and you'll stand out.
Practice your CRA interview answers with AI mock interviews at CareerLift.ai — get instant feedback on your GCP explanations and behavioral responses before the real thing.